M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Niraparib and Copanlisib in Treating Patients with Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 1

Active, not recruiting

Conditions: Deleterious BRCA1 Gene Mutation
Deleterious BRCA2 Gene Mutation
Endometrial Adenocarcinoma
Primary Peritoneal High Grade Serous Adenocarcinoma
Recurrent Endometrial Carcinoma
High Grade Ovarian Serous Adenocarcinoma
Progressive Disease
Platinum-Resistant Ovarian Carcinoma
Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma

Interventions: Drug: Copanlisib
Drug: Niraparib

First Posted Date: 2018-07-13

Last Posted Date: 2025-01-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 31

Registration Number: NCT03586661

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

Phase 3

Recruiting

Conditions: ENSAT Stage I Adrenal Cortex Carcinoma
ENSAT Stage II Adrenal Cortex Carcinoma
ENSAT Stage III Adrenal Cortex Carcinoma

Interventions: Drug: Mitotane
Drug: Cisplatin
Other: Quality-of-Life Assessment
Drug: Etoposide

First Posted Date: 2018-07-11

Last Posted Date: 2024-10-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 240

Registration Number: NCT03583710

Locations: 🇸🇪
Sahlgrenska University Hospital, Gothenburg, Sweden
🇸🇪
Karolinska University Hospital, Stockholm, Sweden
🇸🇪
Akademiska Sjukhuset, Uppsala, Sweden

and more 5 locations

Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Advanced, Metastatic, or Recurrent Cancer

Phase 2

Active, not recruiting

Conditions: Advanced Malignant Solid Neoplasm
Hematopoietic and Lymphoid System Neoplasm
Locally Advanced Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Recurrent Malignant Solid Neoplasm

Interventions: Drug: Dexamethasone
Behavioral: Exercise Intervention
Other: Placebo Administration

First Posted Date: 2018-07-11

Last Posted Date: 2024-12-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 99

Registration Number: NCT03583255

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer

Phase 2

Withdrawn

Conditions: PSA Level Greater Than Ten
Stage IIIB Prostate Cancer AJCC v8
Stage IIIC Prostate Cancer AJCC v8
Stage IVA Prostate Cancer AJCC v8
Stage IV Prostate Cancer AJCC v8
Stage IVB Prostate Cancer AJCC v8
Prostate Adenocarcinoma
Stage III Prostate Cancer AJCC v8
Stage IIB Prostate Cancer AJCC v8
Stage IIIA Prostate Cancer AJCC v8

Interventions: Drug: Hyperpolarized Carbon C 13 Pyruvate
Procedure: Magnetic Resonance Spectroscopic Imaging

First Posted Date: 2018-07-10

Last Posted Date: 2024-10-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 2

Registration Number: NCT03581500

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

Phase 1

Active, not recruiting

Conditions: Recurrent Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8
Stage IVA Lung Cancer AJCC v8

Interventions: Biological: Durvalumab
Drug: Selumetinib
Biological: Tremelimumab

First Posted Date: 2018-07-10

Last Posted Date: 2024-12-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT03581487

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

CD19-Specific T Cells Post AlloSCT

Phase 1

Terminated

Conditions: B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged
Recurrent B Acute Lymphoblastic Leukemia
Recurrent Ph-Like Acute Lymphoblastic Leukemia
Refractory Small Lymphocytic Lymphoma
Recurrent Non-Hodgkin Lymphoma
Refractory B Acute Lymphoblastic Leukemia
Recurrent Small Lymphocytic Lymphoma
Refractory Chronic Lymphocytic Leukemia
Recurrent Chronic Lymphocytic Leukemia
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Interventions: Biological: Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2018-07-09

Last Posted Date: 2021-06-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 4

Registration Number: NCT03579888

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma

Phase 1

Withdrawn

Conditions: Recurrent Diffuse Large B-Cell Lymphoma
Refractory Follicular Lymphoma
CD19 Positive
Refractory Diffuse Large B-Cell Lymphoma
Mantle Cell Lymphoma
Refractory B-Cell Non-Hodgkin Lymphoma
Recurrent Follicular Lymphoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Drug: Cytarabine
Drug: Etoposide
Biological: Filgrastim
Drug: Melphalan
Biological: Rituximab
Biological: Umbilical Cord Blood-derived Natural Killer Cells